Lumateperone 42 mg in an Open-Label Switch Study in Patients with Stable Schizophrenia: Results by Previous Antipsychotic

被引：0
|
作者：
Cutler, Andrew J. [1 ]
Edwards, John B. [2 ]
Durgam, Suresh [2 ]
Mo, Yifan [2 ]
Acosta, Jazmin [2 ]
Davis, Robert E. [2 ]
机构：
[1] SUNY Upstate Med Univ, Dept Psychiat, Lakewood Ranch, FL USA
[2] Intra Cellular Therapies Inc, New York, NY USA
来源：
CNS SPECTRUMS | 2023年 / 28卷 / 02期
关键词：
D O I：
10.1017/S1092852923001645
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：235 / 236
页数：2
相关论文
共 50 条
  • [31] Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study
    Woo, Young Sup
    Yoon, Bo-Hyun
    Jeon, Bong-Hee
    Seo, Jeong Seok
    Nam, Beomwoo
    Lee, Sang-Yeol
    Jae, Young-Myo
    Jang, Sae-Heon
    Eun, Hun Jeong
    Won, Seung-Hee
    Lee, Kwanghun
    Lee, Jonghun
    Bahk, Won-Myong
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2019, 17 (03) : 423 - 431
  • [32] How effective is it to switch among atypical antipsychotics? A randomized, open-label study of algorithm-based antipsychotic treatment to symptomatic patients with schizophrenia in a real-world clinical setting
    Suzuki, T.
    Uchida, H.
    Watanabe, K.
    Tanabe, A.
    Tsunoda, K.
    Nomura, K.
    Niou, S.
    Takeuchi, H.
    Yagi, G.
    Kashima, H.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S269 - S269
  • [33] Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment Post hoc analysis of an open-label, prospective study
    Mei, Tian
    Cai, Shang Li
    Zhuo, Jian Min
    Zhang, Li Li
    MEDICINE, 2019, 98 (03)
  • [34] An open-label trial of discontinuing benzodiazepines in patients with chronic schizophrenia
    Nakajima, Shinichiro
    Uchida, Hiroyuki
    Suzuki, Takefumi
    Tomita, Masayuki
    Tsunoda, Kenichi
    Kitta, Masaya
    Takeuchi, Hiroyoshi
    Nomura, Kensuke
    Watanabe, Koichiro
    Kashima, Haruo
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2007, 27 (04) : 401 - 403
  • [35] An open-label trial of discontinuing benzodiazepines in patients with chronic schizophrenia
    Nakajima, S.
    Uchida, H.
    Tomita, M.
    Kitta, M.
    Shida, H.
    Kitahata, R.
    Takeuchi, H.
    Nomura, K.
    Nagata, A.
    Suzuki, T.
    Tsunoda, K.
    Watanabe, K.
    Yagi, G.
    Kashima, H.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S269 - S269
  • [36] Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE)
    Warren, R. B.
    Barker, J. N. W. B.
    Finlay, A. Y.
    Burden, A. D.
    Kirby, B.
    Armendariz, Y.
    Williams, R.
    Hatchard, C.
    Khare, S.
    Griffiths, C. E. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (01) : 60 - 70
  • [37] Safety and effectiveness of lurasidone for the treatment of schizophrenia in Asian patients: Results of a 26-week open-label extension study
    Higuchi, Teruhiko
    Ishigooka, Jun
    Iyo, Masaomi
    Hagi, Katsuhiko
    ASIA-PACIFIC PSYCHIATRY, 2020, 12 (01)
  • [38] Nefazodone in the adjunctive therapy of schizophrenia: An open-label exploratory study
    Rosenberg, PB
    Rosse, RB
    Schwartz, BL
    Deutsch, SI
    CLINICAL NEUROPHARMACOLOGY, 2000, 23 (04) : 222 - 225
  • [39] SHIATSU AS AN ADJUVANT THERAPY FOR SCHIZOPHRENIA: AN OPEN-LABEL PILOT STUDY
    Lichtenberg, Pesach
    Vass, Agnes
    Ptaya, Hamutal
    Edelman, Shany
    Heresco-Levy, Uriel
    ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE, 2009, 15 (05) : 44 - 46
  • [40] LONG-TERM SAFETY AND TOLERABILITY OF LURASIDONE IN PATIENTS WITH SCHIZOPHRENIA: RESULTS OF A 6-MONTH, OPEN-LABEL STUDY
    Stahl, Steven M.
    Cucchiaro, Josephine
    Simonelli, D.
    Severs, J.
    Loebel, A.
    SCHIZOPHRENIA BULLETIN, 2011, 37 : 322 - 322
12345